Quick orientationEvidence update: 6 October 2026
What is Cerebrolysin?
Cerebrolysin is not one neat little peptide. It is a mixture of small peptides and amino acids produced from porcine brain tissue.
Why people are interested
The potential benefits, unpacked.
Here are the goals and claims that bring readers to this guide. The evidence note shows which part is demonstrated, early research or still a question.
The headline interest
Trials in stroke, traumatic brain injury and dementia have produced mixed, indication-specific results.
What the mechanism suggests
Porcine-brain-derived mixture of low-molecular-weight peptides and amino acids; proposed neurotrophic effects are not attributable to one peptide.
What still needs proving
The key question is whether the claimed benefit has been demonstrated in controlled human studies using the same compound, route and population.
What is it actually doing?
Porcine-brain-derived mixture of low-molecular-weight peptides and amino acids; proposed neurotrophic effects are not attributable to one peptide.
The important distinction is between changing a biomarker or pathway and producing a meaningful outcome that people can feel, measure or sustain.
Results at a glanceHuman evidence
What did the studies actually find?
Human study deep dive
The most informative human evidence we could identify is translated below, with the original source linked.
Study evidenceStudy deep dives
The important studies, translated into normal English.
Each synopsis keeps the trial design, actual results and limitations together. Graphs below are redrawn from the cited numerical results so you can see the size of the effect without having to decode a journal figure.
Cochrane acute ischaemic stroke review — 2023
Systematic review · 7 RCTs · 1,773 participantsThe updated Cochrane review found little or no clear effect on mortality and highlighted uncertainty and risk-of-bias issues across the trials. Other meta-analyses have reached more favourable conclusions on early neurological scores, so this is a genuinely contested evidence base.
A large literature exists, but “lots of studies” does not equal a settled clinical benefit.
What it doesn't prove: Different reviews use different outcomes and trial sets; several studies had manufacturer support.
Read the original study / source ↗
Dosing referenceResearch, licensed & reported protocols
What doses and schedules are actually documented?
Human research or licensed product information is separated from clinic and community practice. These are source-attributed reference protocols, not personalised dosing recommendations.
Human research / licensed or product dosing
| Protocol / context | Amount & frequency | Duration | Titration | Evidence |
|---|---|---|---|---|
| Stroke product guidance | 20–50 mL daily | 10–21 days | No titration | Manufacturer dosage guidance |
| TBI product guidance | 20–50 mL daily | 7–30 days | No titration | Manufacturer guidance |
| Cognition / Alzheimer’s | 10–30 mL daily, 5 days/week | 4 weeks; 2–4 cycles/year | No titration | Manufacturer guidance |
| CARS stroke RCT | 30 mL IV once daily | 21 days | Fixed | Human RCT |
| Large Asian stroke RCT | 30 mL IV once daily | 10 days | Fixed | 1,070-patient RCT |
| 4-week stroke study | 30 mL daily ×7 days →10 mL daily on first 5 days/week through day 30 | 4 weeks | 30→10 mL | Human RCT |
Community / clinic / specialist protocols
| Pattern | Amount & frequency | Cycle | Progression | Status |
|---|---|---|---|---|
| Community cognition use | Often 5–10 mL IM daily or 10–30 mL IV daily in courses | 10–20 days or 5 days/week blocks | Usually fixed | Community largely mirrors product/clinical use |
Cerebrolysin has substantial human dosing literature and official product guidance in countries where used; it is not FDA-approved in the US.
Evidence checked: 7 October 2026
Routes and formulations matter. A topical study does not validate injection; an IV research dose does not establish a fixed SC dose; and evidence for one molecular form must not be silently transferred to another.
Community reportsCommunity reports
What are people actually doing?
Community experience exists, but is anecdotal
Forums discuss schedules, effects and side effects, but posts are uncontrolled self-reports and product identity may be uncertain. Use them to understand what people report—not to estimate efficacy or establish a dose.
View the discussion on Reddit ↗
Safety and uncertaintySafety, side effects & what we don't know
Evidence and regulatory status vary by country and indication.
Product identity, sterility and concentration are additional uncertainties for unlicensed research products. Evidence from an approved medicine or a clinical trial should not be transferred automatically to a differently sourced product.
QuestionsQuestions worth asking
What is the strongest evidence here?
A large literature exists, but “lots of studies” does not equal a settled clinical benefit.
Does a biological mechanism prove the claimed benefit?
No. Receptor activity, cell effects and animal results can justify research, but controlled human outcomes are a separate evidential step.
Is the research protocol a recommended dose?
No. The site reports study protocols to explain the evidence. It does not turn them into personalised self-use instructions.
Primary sourcesStudies, sources & further reading
External links are provided for transparency and further reading. Linking to a study, discussion or organisation does not mean Peptides Peptalk endorses every conclusion on that page.